News

Osborne Clarke advises syndicate of investors led by Gilde Healthcare and Versant Ventures on EUR 16 million financing round of Lava Therapeutics


Written on 24 May 2018

International legal practice Osborne Clarke advises a syndicate of investors led by Gilde Healthcare and Versant Ventures with additional support of MRL Ventures Fund in the EUR 16 million financing round of Lava Therapeutics.

The funding will support development of LAVA’s proprietary pipeline of bispecific gamma-delta (γδ) T cell engagers for the treatment of cancer.

The Osborne Clarke team in Amsterdam was led by partner Herke van Hulst and consisted of Senior Associates Geoffrey Beurskens and Coen Barneveld Binkhuysen and Associate Niels Dolk.

Osborne Clarke’s market leading venture capital team is considered a go-to practice. The team across Europe, Asia and the US combine extensive market knowledge and deep sector expertise to support companies throughout all stages of their developments, from start-up to later stage and growth capital funding, strategic M&A and exits, acting for founders, companies, and financial and strategic investors. The team has particular expertise in the tech, media and comms, financial services and life sciences sectors.

Connect with one of our experts


Herke van Hulst

Partner, Advocaat, The Netherlands

T +31 20 702 8672

Email Herke

Full Biog

Geoffrey Beurskens

Senior Associate, Advocaat, The Netherlands

T +31 20 702 8682

Email Geoffrey

Full Biog

Coen Barneveld Binkhuysen

Senior Associate, Advocaat, The Netherlands

T +31 20 702 8612

Email Coen

Full Biog

Niels Dolk

Associate, Advocaat, The Netherlands

T +31 2 07 02 86 54

Email Niels

Full Biog